Replies to post #196725 on Amarin Corp Plc (AMRN)

[Biobillionair]

Cards- Working in healthcare is a daily uphill battle to do the right thing for patients; it’s unbelievable how fast this has changed over the past 10 years. —BB

Re: Vascepa’s future...To infinity and beyond...

[JJPow]

After prescribing Vascepa for a while i realized - This post is very significant- how many doctors out there are having the exact same issues with having scripts for V rejected or refused for cost- generic L seems to be the go to alternative. As always, Sam, thank you for your efforts!

[NOLA70124]

CardiologyMD:

Thanks for giving us a view from a practitioner's viewpoint on insurance coverage for V.

JT seems to have a different perspective on insurance coverage. Here's what he said at the Goldman presentation:

"As a new drug, we are starting off with the already having pretty good managed-care coverage, considerable portion of our prescriptions currently are off label and the approval rate for managed-care is just a shade under 80%, little over 90% of adult lives on Medicare Part D covered by insurance predominantly tier 2, predominantly unrestricted, and about 80% of lives on commercial insurance covered by insurance. So, again predominantly tier 2, predominantly unrestricted."

For what it's worth -- I'm on Medicare with an AARP/United Healthcare for drug coverage & V is a Tier 4 drug -- so my V prescription is expensive, but I don't care.

My observation is that you (and I) still see a lot of insurance push back on V coverage. This dampens the current numbers that Sam81 provides (Thank you, Sam81, for your reports!). But it also means that the potential for increased script numbers is great -- when insurance coverage in your and my world catches up to JT's world...

[MNBioMike]

Thanks Card. That is consistent with what I've heard from the 20 or so cards that I've spoken with as well. A tidal wave is being formed out in the middle of the ocean....expected arrival 2020.....

[ilovetech]

Cardio, my brother has to a large extent overcome the barriers for approval. He identified an independent pharmacy hungry for business. Between he and the pharmacy, more so with my brother's blessing, the pharmacy communicates with the insurance providers in "ways" that maximize the likelihood of winning approval. It's a win win, because my brother wants the best possible outcome for his patients, and the pharmacy makes money all in good faith that serves the patient's best interest. I recommend that your group do the same.

ILT

[KCSVEN]

By far the biggest reason FDA Priority was huge, End of September is so much better then January for expediting tier changes.

It will take time but in 2021 Generic Lovaza will be wholly replaced by Vascepa (means if that was today the V scripts would double). I believe FDA approval and tier changes in particular are a huge catalyst to be easily 2 billion in sales in 2021 minimum. Tiers will change in 2020 but it's a rolling effect between getting the tier changed and getting people in for there annual visit. 2020 will see accelerated growth but believe 2021 is when it finally goes ballistic. (Inventory increase, insurance tiers well established, marketing penetration high, debt completely paid off).

[PSea]

Even with the discount cards? Surprising to hear cost is playing that big of a role.

[TastyTheElf]

This makes perfect sense, CMD

The hockey stick is coming very soon!